Preventive and/or therapeutic agent for chronic cerebral circulatory failure
A technology of cerebral circulation and therapeutic agents, applied in the direction of organic active ingredients, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve the problems of not disclosing effective or improving and increasing cerebral blood flow, etc., to improve cerebral blood flow. Circulatory metabolism, prevention or treatment of chronic cerebral circulatory insufficiency
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0059] (method)
[0060] 74 patients (40 males, 34 females) (Table-2) with peripheral circulatory insufficiency aged 60 or over were divided into two groups, and 300 mg / day of ticlopidine hydrochloride was administered to the ticlopidine group (43 patients) , 300 mg / day of sarcogrelate hydrochloride was administered to the sarcogrelate group (31 persons) for two years. There was no significant difference in the average age, male to female ratio, and average blood pressure between the ticlopidine group and the sarcogrelate group.
[0061] 〔table 3〕
[0062] Sagrelate group
Ticlopidine group
male / female (person)
17 / 14
23 / 20
age)
71.6±6.4
72.6±5.6
scope
(60~83)
(60~84)
60 years old or above
12 people (38.7%)
11 people (25.6%)
70 years or older
16 people (51.6%)
27 (62.8%)
80 years or older
3 people (9.7%)
5 people (11.6%)
Average blood pressure (mmHg)
...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com